Sonnet biotherapeutics provides fiscal year 2021 second quarter business and earnings update

Son-1010, fully-human il-12 configured using fhab platform, advancing towards ind submission at-the-market offering program resulted in net proceeds of $10.2 million princeton, nj / accesswire / may 17, 2021 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended march 31, 2021 and provided a business update. "over the course of the quarter, we have made several advancements across our pipeline products, most notably of which are the completion of non-human primate (nhp) toxicology study of son-080 and the completion of a repeat dose study of son-1010 in nhps," commented pankaj mohan, ph.d.
SONN Ratings Summary
SONN Quant Ranking